Table 5.
Toxicity profile
| Adverse events | All grades | Grades 3–4 |
|---|---|---|
| Asthenia | 49 (72%) | 7 (10%) |
| Hypertension | 27 (39%) | 2 (3%) |
| Hypothyroidism | 17 (25%) | 1 (1.5%) |
| Diarrhea | 17 (25%) | 0 |
| Dysphonia | 16 (23.5%) | 0 |
| Anemia | 13 (19%) | 2 (3%) |
| Thrombocytopenia | 11 (16%) | 2 (3%) |
| Hand–Foot Syndrome | 9 (13%) | 1 (1.5%) |
| Leukopenia | 8 (12%) | 2 (3%) |
| Hepatotoxicitya | 8 (12%) | 1 (1.5%) |
| Increased creatinine | 8 (12%) | 0 |
| Nausea | 7 (10%) | 1 (1.5%) |
| Proteinuriab | 3 (6.4%) | 0 |
| Colitis | 4 (6%) | 2 (3%) |
| Mucositis | 4 (6%) | 1 (1.5%) |
| Weight loss | 4 (6%) | 0 |
| Dysgeusia | 3 (4%) | 0 |
| Arthralgia | 2 (3%) | 1 (1.5%) |
| Rash | 2 (3%) | 0 |
aAST and ALT elevations.
bOnly available data in 47 patients.